Utilizing its proprietary DNA technology to write synthetic libraries, Twist Biopharma provides end-to-end antibody discovery and optimization solutions.  To enable the discovery of functional GPCR antibodies, we grafted a large number of GPCR-binding motifs into a focused antibody library.  By incorporating these motifs into the antibody heavy chain CDR3, we developed our first generation GPCR library.  Another approach mined the patented GPCR antibody sequences and used the sequence information to guide the design of another synthetic library.  We demonstrate the utility both libraries to discover potent functional antibodies against multiple GPCR targets.  In this talk, Aaron Sato, CSO, Biopharma, will present several case studies on the use of this platform.